Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| Weiss Ratings | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.96 | |||
| Price History | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -44.55% | |||
| 30-Day Total Return | -55.74% | |||
| 60-Day Total Return | -44.43% | |||
| 90-Day Total Return | -78.71% | |||
| Year to Date Total Return | -49.58% | |||
| 1-Year Total Return | -81.78% | |||
| 2-Year Total Return | -84.81% | |||
| 3-Year Total Return | -81.52% | |||
| 5-Year Total Return | -82.27% | |||
| 52-Week High % Change | -87.00% | |||
| 52-Week Low % Change | 29.65% | |||
| Price | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.83 | |||
| 52-Week Low Price | $0.28 | |||
| 52-Week Low Price (Date) | Mar 03, 2025 | |||
| 52-Week High Price (Date) | Mar 12, 2024 | |||
| Valuation | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 132.92M | |||
| Enterprise Value | -4.74M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.75 | |||
| Earnings Per Share Growth | -0.62% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 25.53 | |||
| Price/Book (Q) | 0.74 | |||
| Enterprise Value/Revenue (TTM) | -0.91 | |||
| Price | $0.39 | |||
| Enterprise Value/EBITDA (TTM) | 0.02 | |||
| Enterprise Value/EBIT | 0.02 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 361.49M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 281 863 3000 | |||
| Address | 2445 Technology Forest Boulevard The Woodlands, TX 77381 | |||
| Website | www.lexpharma.com | |||
| Country | United States | |||
| Year Founded | 1995 | |||
| Profitability | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4,037.42% | |||
| Profit Margin | -4,138.32% | |||
| Management Effectiveness | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -44.16% | |||
| Return on Equity | -- | |||
| Income Statement | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.23M | |||
| Total Revenue (TTM) | 5.23M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -67.67M | |||
| EBITDA (TTM) | -210.56M | |||
| EBIT (TTM) | -211.12M | |||
| Net Income (TTM) | -216.39M | |||
| Net Income Avl. to Common (TTM) | -216.39M | |||
| Total Revenue Growth (Q YOY) | 980.25% | |||
| Earnings Growth (Q YOY) | -28.28% | |||
| EPS Diluted (TTM) | -0.75 | |||
| EPS Diluted Growth (Q YOY) | 13.09% | |||
| Balance Sheet | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 258.37M | |||
| Cash Per Share (Q) | $0.71 | |||
| Total Current Assets (Q) | 268.61M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 178.51M | |||
| Current Ratio (Q) | 7.452 | |||
| Book Value Per Share (Q) | $0.49 | |||
| Total Assets (Q) | 321.12M | |||
| Total Current Liabilities (Q) | 36.05M | |||
| Total Debt (Q) | 105.87M | |||
| Total Liabilities (Q) | 142.61M | |||
| Total Common Equity (Q) | 178.51M | |||
| Cash Flow | LXRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -17.18M | |||
| Cash from Financing (TTM) | 238.45M | |||
| Net Change in Cash (TTM) | 13.44M | |||
| Levered Free Cash Flow (TTM) | -126.94M | |||
| Cash from Operations (TTM) | -207.84M | |||
